NY-IFF
11.1.2023 22:16:44 CET | Business Wire | Press release
IFF (NYSE:IFF) today announced it has qualified for the third consecutive year as a constituent of the Dow Jones Sustainability Indices (DJSI), a family of benchmarks widely regarded as one of the world’s leading tools for investors to integrate sustainability considerations into their portfolios to increase long-term shareholder value. Named to both the 2022 World Index and the North America Index, IFF is the only company in its industry to be included.
The S&P Global Corporate Sustainability Assessment (CSA) serves as the basis for the ESG scores that power the DJSI and its prestigious list of selected companies. IFF’s total CSA score places the Company among the top 10 percent of sustainability performers in the world, as assessed from among the 2,500 largest companies in the S&P Global Broad Market Index (BMI). Similarly, IFF ranks among the top 20 percent of the 600 largest companies in the S&P Global BMI in North America.
The distinction of achieving an annual place on the DJSI – and even increasing its score from the prior year – underscores IFF’s ongoing leadership position in environmental, social and governance (ESG) management, despite significantly increasing its size and complexity following the merger with DuPont’s Nutrition & Biosciences division in 2021. The Company’s CSA disclosures scored in 2022 were the first to reflect its post-merger performance and outcomes, including those based on an increase from nearly 14,000 employees to more than 24,000, and an expanded global footprint.
IFF was also recognized for leadership in corporate transparency and performance on climate change by global environmental non-profit CDP, securing a place on its 2022 ‘A List’ for climate change for the eighth consecutive year. Based on IFF’s post-merger data reported through CDP’s 2022 Climate Change questionnaire, IFF is one of a small number of companies out of nearly 15,000 scored that were named to the ‘A List’ for climate change, based on its actions to reduce emissions, mitigate climate risks and develop the low-carbon economy. IFF also received an “A-“ in CDP’s other two categories for action to protect water security risks and forests.
“We’re very proud to be recognized by S&P Global and CDP for our ESG excellence in 2022,” said Frank Clyburn, CEO, IFF. “We credit these achievements to the laser focus of our global team—striving to be the most sustainable company we can be—guided by our ambitious Do More Good Plan. We know we have more work to do in 2023 and beyond, but these external validations continue to inspire us and are a reminder that we’re heading in the right direction.”
IFF’s Do More Good Plan is a comprehensive ESG roadmap aligned with the Company’s purpose of applying science and creativity for a better world, organized by the four strategic focus areas of Sustainable Solutions, Climate & Planetary Health, Equity & Wellbeing and Transparency & Accountability.
The 2022 DJSI and CDP recognitions follow several other competitive ESG ratings IFF received during the year, including being:
- Awarded the 2022 EcoVadis Platinum sustainability rating for the second time, placing IFF among the top 1% of companies assessed;
- Named for the first time to the 2022 Bloomberg Gender Equality Index for its commitment to transparency and setting a new standard in gender-related data reporting; and
- Recertified for the second consecutive year by the Economic Dividends for Gender Equality (EDGE) at the Move level globally for its commitment to workplace diversity and intersectional issues.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005902/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
